Join Conscio Group upcoming webinar on December 12 at 2:00 PM CET (expected length up to 2 hours), where industry experts will discuss the latest trends in regulation, R&D and clinical testing. In our session we will particularly explore potential regulatory changes regarding the waiver of Phase 3 efficacy studies.

Topics include:

  • Navigating Biosimilar Regulations: Evolution, Challenges, and Future Directions
  • Common pitfalls on the path from R&D to biotech product commercialization
  • Strategies for successful bioassay transfer and validation – the importance of standardization

Speakers: Elena Guillen Benitez, MD, PhD from Leiden University Medical Center, Martin Baur from Midas Pharma, and Klemens Weitenthaler from Conscio Group.

Moderator: Stephan Holl, CEO Conscio Group

Gain insider knowledge on the biosimilar industry – register here!

If you would like to view the recording of the webinar, please contact us today and we will be happy to give you exclusive access to it on our YouTube channel.

Additional News

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.

  • 20 November 2025

    Webinar: Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar from biosimilar series.

ALL POSTS